The Effect of Different Formulations of Praziquantel in Reducing Worms in the Prepatent Period of Schistosomiasis in Murine Models

Schistosomiasis is a widely distributed parasitic disease and one of the most important neglected tropical diseases globally, for which Praziquantel® (PZQ) is the only available treatment. In this context, tests with new PZQ formulations become relevant for disease control. This study evaluated the effects of PZQ treatment in the prepatent phase of schistosomiasis using two formulations: nanoencapsulated (PZQ-NANO) and active pharmaceutical ingredient (PZQ-API). Five experimental groups were established, for which the following serological parameters were evaluated: ALT, AST, ALP, and TP. Animals treated with PZQ-API at 15 and 30 days post-infection showed decreased eggs per gram of feces (EPG) compared to untreated infected animals. The same animals showed reductions of 63.6 and 65.1%, respectively, at 60 days post-infection. Animals treated with PZQ-NANO experienced no significant changes in EPG at any time of observation. Animals treated with either PZQ-API or PZQ-NANO had higher ALT and AST levels in the patent period (60 and 90 days post-infection). Treatment with PZQ, either API or NANO, at 15 days post-infection reduced AST, ALT, and TP levels. It is concluded that prepatent treatment with PZQ-API can reduce the parasite load of infected animals and that treatment at 15 days post-infection can prevent increased serum levels of ALT, AST, and TP.Fil: Paulino, Érica Tex. Fundación Oswaldo Cruz; BrasilFil: Ribeiro de Lima, Monique. Fundación Oswaldo Cruz; BrasilFil: Viçosa, Alessandra Lifsitch. Fundación Oswaldo Cruz; BrasilFil: Hooper da Silva, Cleber. Fundación Oswaldo Cruz; BrasilFil: Salomon, Claudio Javier. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Química Rosario. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Química Rosario; ArgentinaFil: Real, Daniel Andres. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Química Rosario. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Química Rosario; ArgentinaFil: Leonardi, Darío. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Química Rosario. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Química Rosario; ArgentinaFil: Mello Silva, Clélia Christina. Fundación Oswaldo Cruz; BrasilFil: Almeida de Moraes Neto, Antonio Henrique. Fundación Oswaldo Cruz; Brasi

Desenvolvimento de um medicamento brasileiro nanoencapsulado para o tratamento da esquistossomose

Schistosomiasis is a parasitic disease that, according to the World Health Organization, constitutes a major public health problem associated with severe morbidity, mostly children in preschool age. The administration of drugs in children always constitutes a difficult task, especially when formulations are not developed specifically for pediatric use, when high doses of drug are required and the drug has a bitter taste, as in the case of praziquantel. Polymer nanoparticles are promising systems for development of encapsulated drugs with low water solubility and bitter taste, due to the good physical and chemical stability, adequate biocompatibility and simple manufacturing processes. Moreover, they can enhance the bioavailability and reduce variability of treatment among patients. Poly(methyl methacrylate) doped with praziquantel was produced through a miniemulsion polymerization process to compose a pediatric pharmaceutical suspension. Nanoparticles were characterized in terms of physico-chemical properties, toxicological properties and biological activity in mice, being concluded that obtained results were satisfactory. The results were encapsulation rate around 90%, absence of chemical interaction drug - polymer and the presence of biological activity. A collaborative approach was used for this development, involving national partnerships and independent funding mechanisms, a powerful pathway for development of drugs for neglected diseases.A esquistossomose é uma doença parasitária que, segundo a Organização Mundial da Saúde, é um dos principais problemas de saúde pública associados à morbidade severa, sendo boa parte crianças. A administração de medicamentos em crianças constitui uma tarefa difícil, principalmente quando não há formulações pediátricas, quando altas doses de fármaco são requeridas e o fármaco apresenta um sabor amargo, como é o caso do praziquantel. Nanopartículas poliméricas são sistemas promissores para o desenvolvimento de fármacos com baixa hidrossolubilidade e gosto ruim, apresentam estabilidade físico-química, biocompatibilidade e fáceis processos de produção. Podem ainda proporcionar o aumento da biodisponibilidade e redução da variabilidade do tratamento entre pacientes. O polímero poli(metacrilato de metila) com o praziquantel encapsulado foi sintetizado pelo processo de polimerização em miniemulsão para compor uma suspensão farmacêutica pediátrica. As nanopartículas foram caracterizadas em termos das propriedades físico-químicas, toxicológicas e da atividade biológica em camundongos. Os resultados encontrados foram satisfatórios, taxa de encapsulamento de 90%, ausência de interação química fármaco - polímero e presença de atividade biológica. Uma abordagem colaborativa foi utilizada para este desenvolvimento, envolvendo parcerias nacionais e mecanismos de financiamento independentes, uma maneira nova e poderosa de desenvolver medicamentos para doenças negligenciadas

The repositioned drugs disulfiram/diethyldithiocarbamate combined to benznidazole: Searching for Chagas disease selective therapy, preventing toxicity and drug resistance

Chagas disease (CD) affects at least 6 million people in 21 South American countries besides several thousand in other nations all over the world. It is estimated that at least 14,000 people die every year of CD. Since vaccines are not available, chemotherapy remains of pivotal relevance. About 30% of the treated patients cannot complete the therapy because of severe adverse reactions. Thus, the search for novel drugs is required. Here we tested the benznidazole (BZ) combination with the repositioned drug disulfiram (DSF) and its derivative diethyldithiocarbamate (DETC) upon Trypanosoma cruzi in vitro and in vivo. DETC-BZ combination was synergistic diminishing epimastigote proliferation and enhancing selective indexes up to over 10-fold. DETC was effective upon amastigotes of the BZ- partially resistant Y and the BZ-resistant Colombiana strains. The combination reduced proliferation even using low concentrations (e.g., 2.5 µM). Scanning electron microscopy revealed membrane discontinuities and cell body volume reduction. Transmission electron microscopy revealed remarkable enlargement of endoplasmic reticulum cisternae besides, dilated mitochondria with decreased electron density and disorganized kinetoplast DNA. At advanced stages, the cytoplasm vacuolation apparently impaired compartmentation. The fluorescent probe H2-DCFDA indicates the increased production of reactive oxygen species associated with enhanced lipid peroxidation in parasites incubated with DETC. The biochemical measurement indicates the downmodulation of thiol expression. DETC inhibited superoxide dismutase activity on parasites was more pronounced than in infected mice. In order to approach the DETC effects on intracellular infection, peritoneal macrophages were infected with Colombiana trypomastigotes. DETC addition diminished parasite numbers and the DETC-BZ combination was effective, despite the low concentrations used. In the murine infection, the combination significantly enhanced animal survival, decreasing parasitemia over BZ. Histopathology revealed that low doses of BZ-treated animals presented myocardial amastigote, not observed in combination-treated animals. The picrosirius collagen staining showed reduced myocardial fibrosis. Aminotransferase de aspartate, Aminotransferase de alanine, Creatine kinase, and urea plasma levels demonstrated that the combination was non-toxic. As DSF and DETC can reduce the toxicity of other drugs and resistance phenotypes, such a combination may be safe and effective

Translational Research on Chagas Disease: Focusing on Drug Combination and Repositioning

Chagas disease, caused by the protozoan Trypanosoma cruzi, is a major neglected disease endemic to Latin America, associated to significant morbimortality comprising a remarkable socioeconomic problem mainly for low-income tropical populations. The present chapter focuses translational research on Chagas disease, approaching drug combinations and repositioning, particularly exploiting the parasite oxidative stress by prospecting prooxidant compounds combined with antagonists of antioxidant systems, for developing low-cost and safe therapies for this infection. The pertinent literature on protozoal parasitic diseases is reviewed as well as on repurposing disulfiram aiming the combination with the Chagas disease drug of choice benznidazole. Both disulfiram and its first derivative sodium diethyldithiocarbamate (DETC) are able not only to inhibit p-glycoprotein, possibly reverting resistance phenotypes, but also to reduce toxicity of numerous other drugs, heavy metals, etc. Therefore, this innovation, presently in clinical research, may furnish a novel therapeutic for T. cruzi infections overcoming the adverse effects and refractory cases that impair the effectiveness of Chagas disease treatment

Captopril oral solution for pediatric use: formulation, stability study and palatability assessment in vivo

The aim of this work was to develop an oral solution of captopril at 5 mg/mL preservative-free. Two formulations were prepared, one containing sweetener (formulation 1) and the other without this excipient (formulation 2). The results found of validation parameters from analytical method performed by HPLC for captopril were, linearity 0.9998, the limit of detection 15.71 µg/mL, the limit of quantification 47.60 µg/mL, repeatability 1.05%, intermediate precision 2.42%, accuracy intraday 101,53%, accuracy inter-day 99.85%. Moreover, the results found for captopril disulfide were, linearity 0.9999, limit of detection 0.65 µg/mL, limit of quantification 1.96 µg/mL, repeatability 2.28%, intermediate precision 1.51%, accuracy intraday 101.36%, accuracy inter-day 100.29%. The appearance of formulations was clear and colorless, pH measures were 3.12 and 3.04, dosage of captopril and captopril disulfide were 99.45% and 99.82%, 0.24% and 0.12% for formulation 1 and formulation 2, respectively. The stability study demonstrated that the concentration of captopril and captopril disulfide in the formulations was > 90% and below 3%, respectively. The in vivo palatability study in animals and humans showed that Formulation 1 containing the sweetener had better acceptance. Thus, the sweetener was able to improve the unpleasant taste of the formulation

Development of a brazilian nanoencapsulated drug for schistosomiasis treatment

Submitted by Nuzia Santos ([email protected]) on 2018-09-24T18:38:29Z No. of bitstreams: 1 Desenvolvimento de um medicamento brasileiro nanoencapsulado.pdf: 717455 bytes, checksum: b1a95816e0eb7137bb22fc3b73c5a50d (MD5)Approved for entry into archive by Nuzia Santos ([email protected]) on 2018-09-24T18:55:52Z (GMT) No. of bitstreams: 1 Desenvolvimento de um medicamento brasileiro nanoencapsulado.pdf: 717455 bytes, checksum: b1a95816e0eb7137bb22fc3b73c5a50d (MD5)Made available in DSpace on 2018-09-24T18:55:53Z (GMT). No. of bitstreams: 1 Desenvolvimento de um medicamento brasileiro nanoencapsulado.pdf: 717455 bytes, checksum: b1a95816e0eb7137bb22fc3b73c5a50d (MD5) Previous issue date: 2013Fundação Oswaldo Cruz. Produção e Inovação em Saúde. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto de Técnologia em Fármaco. Rio de Janeiro, RJ, BrasilFundação Oswaldo Cruz. Centro de Pesquisa Renê Rachou. Belo Horizonte, MG, Brasil.Fundação Oswaldo Cruz. Centro de Pesquisa Renê Rachou. Belo Horizonte, MG, Brasil.Fundação Oswaldo Cruz. Centro de Pesquisa Renê Rachou. Belo Horizonte, MG, BrasilFundação Oswaldo Cruz. Instituto Nacional de Controle de Qualidade em Saúde. Rio de Janeiro, RJ, BrasilUniversidade Federal do Rio Grande do Sul. Porto Alegre, RS, BrasilUniversidade Federal do Rio de Janeiro. Escola de Química. Rio de Janeiro, RJ, BrasilUniversidade Federal do Rio de Janeiro. Engenharia Química. Rio de Janeiro, RJ, BrasilA esquistossomose é uma doença parasitária que, segundo a Organização Mundial da Saúde, é um dos principais problemas de saúde pública associados à morbidade severa, sendo boa parte crianças. A administração de medicamentos em crianças constitui uma tarefa difícil, principalmente quando não há formulações pediátricas, quando altas doses de fármaco são requeridas e o fármaco apresenta um sabor amargo, como é o caso do praziquantel. Nanopartículas poliméricas são sistemas promissores para o desenvolvimento de fármacos com baixa hidrossolubilidade e gosto ruim, apresentam estabilidade físico-química, biocompatibilidade e fáceis processos de produção. Podem ainda proporcionar o aumento da biodisponibilidade e redução da variabilidade do tratamento entre pacientes. O polímero poli (metacrilato de metila) com o praziquantel encapsulado foi sintetizado pelo processo de polimerização em miniemulsão para compor uma suspensão farmacêutica pediátrica. As nanopartículas foram caracterizadas em termos das propriedades físico-químicas, toxicológicas e da atividade biológica em camundongos. Os resultados encontrados foram satisfatórios, taxa de encapsulamento de 90%, ausência de interação química fármaco-polímero e presença de atividade biológica. Uma abordagem colaborativa foi utilizada para esse desenvolvimento, envolvendo parcerias nacionais e mecanismos de financiamento independentes, uma maneira nova e poderosa de desenvolver medicamentos para doenças negligenciadasSchistosomiasis is a parasitic disease that, according to the World Health Organization, constitutes a major public health problem associated with severe morbidity, mostly children in preschool age. The administration of drugs in children always constitutes a difficult task, especially when formulations are not developed specifically for pediatric use, when high doses of drug are required and the drug has a bitter taste, as in the case of praziquantel. Polymer nanoparticles are promising systems for development of encapsulated drugs with low water solubility and bitter taste, due to the good physical and chemical stability, adequate biocompatibility and simple manufacturing processes. Moreover, they can enhance the bioavailability and reduce variability of treatment among patients. Poly (methyl methacrylate) doped with praziquantel was produced through a miniemulsion polymerization process to compose a pediatric pharmaceutical suspension. Nanoparticles were characterized in terms of physico-chemical properties, toxicological properties and biological activity in mice, being concluded that obtained results were satisfactory. The results were encapsulation rate around 90%, absence of chemical interaction drug - polymer and the presence of biological activity. A collaborative approach was used for this development, involving national partnerships and independent funding mechanisms, a powerful pathway for development of drugs for neglected diseases